ANDA 202126, held by Gland Pharma. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 202126 (Dexmedetomidine Hydrochloride), held by Gland Pharma, was first approved by FDA on Aug 20, 2015, with 5 approved supplements and 0 published complete response letters.
1.1 Intensive Care Unit Sedation Dexmedetomidine injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedetomidine injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine injection has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine injection is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) ยท injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| Mar 20, 2026 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Mar 20, 2026 | Supplement 11Labeling ยท Standard review | Approved | None posted |
| Feb 19, 2021 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Aug 25, 2017 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Aug 25, 2017 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Aug 20, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters